Table 1

Baseline characteristics for 28 LPL patients enrolled in the study

MedianRange
Age, y 59.5 33-75 
Male/female 18/10 N/A 
Previously treated, n (%) 23 (82.1) N/A 
Median prior therapies, n 0-5 
Bone marrow involvement, % 30 5-90 
Adenopathy/splenomegaly, n (%) 5 (17.9) N/A 
Serum IgM, mg/dL 3510 622-12 000 
B2M, mg/L 3.1 1.3-6.9 
Hematocrit, % 35.0 24.4-42.8 
Platelets, 1000/μL 232 72-486 
Leukocytes, 1000/μL 5.45 2-13 
MedianRange
Age, y 59.5 33-75 
Male/female 18/10 N/A 
Previously treated, n (%) 23 (82.1) N/A 
Median prior therapies, n 0-5 
Bone marrow involvement, % 30 5-90 
Adenopathy/splenomegaly, n (%) 5 (17.9) N/A 
Serum IgM, mg/dL 3510 622-12 000 
B2M, mg/L 3.1 1.3-6.9 
Hematocrit, % 35.0 24.4-42.8 
Platelets, 1000/μL 232 72-486 
Leukocytes, 1000/μL 5.45 2-13 

B2M indicates beta 2 microglobulin; and N/A, not applicable.

Close Modal

or Create an Account

Close Modal
Close Modal